Genome-wide association study (GWAS) approaches to cancer have been successful at identifying novel susceptibility loci, but there remains a fundamental gap in understanding the biological and clinical relevance of these discoveries. This problem is especially acute as there is an urgent need to translate basic scientific advancements into clinically relevant deliverables that will impact cancer patient care. The long-term goal of this research proposal is to discover the heritable component of neuroblastoma, an important childhood cancer that continues to result in significant morbidity and mortality, and to use this knowledge to develop novel therapeutic strategies. The primary objective of this competitive renewal application, based on the published and unpublished results from the first 4 years of funding, is to discover how host genetic architecture explains neuroblastoma susceptibility and patient survival, while also extending our initial findings that genes uncovered by our GWAS play a central role in tumor progression and maintenance. The central hypothesis to be explored here is that heritable DNA variation influences the initiation of neuroblastoma, the clinical course of the disease, and patient outcomes. This hypothesis builds on our identification of multiple common and rare DNA variations associated with neuroblastoma, the observation that many of the genes identified through these efforts impart oncogenic dependencies in established tumors, and the fact that recurrent somatic mutations are exceeding rare, even in the most aggressive subsets of this disease. The motivation for the proposed research is the urgent need to improve high-risk neuroblastoma survival rates and decrease treatment-related morbidities. We will test our central hypothesis in three specific aims: 1) Discover common and rare DNA variants that are associated with neuroblastoma;2) Identify the DNA polymorphisms that predict neuroblastoma patient survival;and 3) Determine how genes identified by the neuroblastoma GWAS act as oncogenic drivers of the malignant phenotype.
The first Aim will continue our discovery efforts by increasing the resolution of the scan and doubling the number of cases and controls, with the goal of delivering the identifiable heritable component of neuroblastoma.
Aim 2 is devoted to a GWAS within the neuroblastoma cases to define genetic determinants of patient survival, and this will build on our preliminary data identifying potential tumor cell intrinsic mechanisms of chemotherapy resistance via this approach.
The final Aim will determine the mechanism by which genes identified by the most robust association signals act as tumor suppressors or oncogenes in neuroblastoma cells, again building on our extensive preliminary data. We consider this project significant because it will define DNA variation, genes and pathways critical to neuroblastoma initiation and progression, and thus provide insights that will be actionable in the clinic and ultimately result in improved cure rates.

Public Health Relevance

This research project is relevant to public health because the discovery of how common and rare DNA variation influence neuroblastoma susceptibility, patient outcomes and define oncogenic vulnerabilities in tumor cells will lead to more precise clinical biomarkers and therapies. The proposed research is highly relevant to the NIH mission and the urgent unmet need of developing rational evidence-based strategies to reduce the burden of cancer in general, and neuroblastoma in particular.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project (R01)
Project #
Application #
Study Section
Cancer Genetics Study Section (CG)
Program Officer
Zanetti, Krista A
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Children's Hospital of Philadelphia
United States
Zip Code
Cimmino, Flora; Avitabile, Marianna; Diskin, Sharon J et al. (2018) Fine mapping of 2q35 high-risk neuroblastoma locus reveals independent functional risk variants and suggests full-length BARD1 as tumor-suppressor. Int J Cancer 143:2828-2837
Zhu, Shizhen; Zhang, Xiaoling; Weichert-Leahey, Nina et al. (2017) LMO1 Synergizes with MYCN to Promote Neuroblastoma Initiation and Metastasis. Cancer Cell 32:310-323.e5
Tolbert, Vanessa P; Coggins, Grace E; Maris, John M (2017) Genetic susceptibility to neuroblastoma. Curr Opin Genet Dev 42:81-90
Harenza, Jo Lynne; Diamond, Maura A; Adams, Rebecca N et al. (2017) Corrigendum: Transcriptomic profiling of 39 commonly-used neuroblastoma cell lines. Sci Data 4:170183
Chang, Xiao; Zhao, Yan; Hou, Cuiping et al. (2017) Common variants in MMP20 at 11q22.2 predispose to 11q deletion and neuroblastoma risk. Nat Commun 8:569
Harenza, Jo Lynne; Diamond, Maura A; Adams, Rebecca N et al. (2017) Transcriptomic profiling of 39 commonly-used neuroblastoma cell lines. Sci Data 4:170033
Applebaum, Mark A; Vaksman, Zalman; Lee, Sang Mee et al. (2017) Neuroblastoma survivors are at increased risk for second malignancies: A report from the International Neuroblastoma Risk Group Project. Eur J Cancer 72:177-185
Mazul, Angela L; Siega-Riz, Anna Maria; Weinberg, Clarice R et al. (2016) A family-based study of gene variants and maternal folate and choline in neuroblastoma: a report from the Children's Oncology Group. Cancer Causes Control 27:1209-18
Walsh, Kyle M; Whitehead, Todd P; de Smith, Adam J et al. (2016) Common genetic variants associated with telomere length confer risk for neuroblastoma and other childhood cancers. Carcinogenesis 37:576-582
Bosse, Kristopher R; Maris, John M (2016) Advances in the translational genomics of neuroblastoma: From improving risk stratification and revealing novel biology to identifying actionable genomic alterations. Cancer 122:20-33

Showing the most recent 10 out of 33 publications